RxDoctor Payments DataLook up a doctor →

Edmund Tai, MD

Anatomic Pathology & Clinical Pathology · Mountain View, CANPI 1487669933

Payments from drug & device makers

$177,368in general payments, 2019–2025

Across 243 payments — averaging $729.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$128K
  • Merck$17K
  • AstraZeneca$15K
  • Novartis$7K
  • Genentech USA, Inc.$3K
  • Boehringer Ingelheim$3K
  • plus $5K from 20 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$177,368 in reported general payments places this provider in the 95th percentile of 814 anatomic pathology & clinical pathology providers in California.

See all anatomic pathology & clinical pathology providers in California

Medicare billing

Part B allowed, 2024
$3,408,678
Medicare patients
18,491
Services billed
238,680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Mountain View

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →